261 related articles for article (PubMed ID: 21738705)
21. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
Shaw RJ
Acta Physiol (Oxf); 2009 May; 196(1):65-80. PubMed ID: 19245654
[TBL] [Abstract][Full Text] [Related]
22. Loss of TSC2 confers resistance to ceramide and nutrient deprivation.
Guenther GG; Liu G; Ramirez MU; McMonigle RJ; Kim SM; McCracken AN; Joo Y; Ushach I; Nguyen NL; Edinger AL
Oncogene; 2014 Apr; 33(14):1776-87. PubMed ID: 23604129
[TBL] [Abstract][Full Text] [Related]
23. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
24. Lysosomal recruitment of TSC2 is a universal response to cellular stress.
Demetriades C; Plescher M; Teleman AA
Nat Commun; 2016 Feb; 7():10662. PubMed ID: 26868506
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.
Medvetz D; Priolo C; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):3-8. PubMed ID: 25298408
[TBL] [Abstract][Full Text] [Related]
26. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.
Balgi AD; Fonseca BD; Donohue E; Tsang TC; Lajoie P; Proud CG; Nabi IR; Roberge M
PLoS One; 2009 Sep; 4(9):e7124. PubMed ID: 19771169
[TBL] [Abstract][Full Text] [Related]
27. ULK1 inhibits the kinase activity of mTORC1 and cell proliferation.
Jung CH; Seo M; Otto NM; Kim DH
Autophagy; 2011 Oct; 7(10):1212-21. PubMed ID: 21795849
[TBL] [Abstract][Full Text] [Related]
28. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.
Menon S; Yecies JL; Zhang HH; Howell JJ; Nicholatos J; Harputlugil E; Bronson RT; Kwiatkowski DJ; Manning BD
Sci Signal; 2012 Mar; 5(217):ra24. PubMed ID: 22457330
[TBL] [Abstract][Full Text] [Related]
29. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS.
Zhang J; Kim J; Alexander A; Cai S; Tripathi DN; Dere R; Tee AR; Tait-Mulder J; Di Nardo A; Han JM; Kwiatkowski E; Dunlop EA; Dodd KM; Folkerth RD; Faust PL; Kastan MB; Sahin M; Walker CL
Nat Cell Biol; 2013 Oct; 15(10):1186-96. PubMed ID: 23955302
[TBL] [Abstract][Full Text] [Related]
30. mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition.
Bhaskar PT; Nogueira V; Patra KC; Jeon SM; Park Y; Robey RB; Hay N
Mol Cell Biol; 2009 Sep; 29(18):5136-47. PubMed ID: 19620286
[TBL] [Abstract][Full Text] [Related]
31. AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells.
Agarwal S; Bell CM; Rothbart SB; Moran RG
J Biol Chem; 2015 Nov; 290(46):27473-86. PubMed ID: 26391395
[TBL] [Abstract][Full Text] [Related]
32. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.
Matthew EM; Hart LS; Astrinidis A; Navaraj A; Dolloff NG; Dicker DT; Henske EP; El-Deiry WS
Cell Cycle; 2009 Dec; 8(24):4168-75. PubMed ID: 20054236
[TBL] [Abstract][Full Text] [Related]
33. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
[TBL] [Abstract][Full Text] [Related]
34. TSC2 mediates hyperosmotic stress-induced inactivation of mTORC1.
Plescher M; Teleman AA; Demetriades C
Sci Rep; 2015 Sep; 5():13828. PubMed ID: 26345496
[TBL] [Abstract][Full Text] [Related]
35. Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex.
Kim SG; Hoffman GR; Poulogiannis G; Buel GR; Jang YJ; Lee KW; Kim BY; Erikson RL; Cantley LC; Choo AY; Blenis J
Mol Cell; 2013 Jan; 49(1):172-85. PubMed ID: 23142078
[TBL] [Abstract][Full Text] [Related]
36. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
37. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
38. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling.
Wang X; Fonseca BD; Tang H; Liu R; Elia A; Clemens MJ; Bommer UA; Proud CG
J Biol Chem; 2008 Nov; 283(45):30482-92. PubMed ID: 18676370
[TBL] [Abstract][Full Text] [Related]
39. mTORC1 signaling and regulation of pancreatic β-cell mass.
Blandino-Rosano M; Chen AY; Scheys JO; Alejandro EU; Gould AP; Taranukha T; Elghazi L; Cras-Méneur C; Bernal-Mizrachi E
Cell Cycle; 2012 May; 11(10):1892-902. PubMed ID: 22544327
[TBL] [Abstract][Full Text] [Related]
40. Tissue-specific ablation of Tsc1 in pancreatic beta-cells.
Mori H; Guan KL
Methods Mol Biol; 2012; 821():407-19. PubMed ID: 22125081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
